加载中
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
收盘时
US$3.25
−US$0.23 · -6.61%
盘后
US$3.73
+US$0.48 · +14.77%
10月13日 16:25 ET
盘中时间采用ET。市场数据可能有所延迟。
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
日内区间
当前US$3.25
52周区间
当前US$3.25
盘中时间采用ET。市场数据可能有所延迟。
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
日内区间
当前US$3.25
52周区间
当前US$3.25
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | 8.9万 USD | — |
| 毛利 | — | — | — | −8.9万 USD | — |
| 研究与开发 | 622.7万 USD | 569.8万 USD | 727.4万 USD | 641.6万 USD | 308.2万 USD |
| 销售、一般及管理费用 | 485.8万 USD | 420.4万 USD | 477.5万 USD | 704.7万 USD | 250.5万 USD |
| 营业费用 | 1108.5万 USD | 990.2万 USD | 1204.9万 USD | 1346.3万 USD | 558.7万 USD |
| 利息收入 | 1.3万 USD | 2000 USD | 17.8万 USD | 9.1万 USD | — |
| 利息支出 | — | 31.1万 USD | 55万 USD | 1.5万 USD | 115.4万 USD |
| 折旧和摊销 | 1.6万 USD | 2.2万 USD | 2.1万 USD | 8.9万 USD | 3000 USD |
| 营业利润 | −1108.5万 USD | −990.2万 USD | −1204.9万 USD | −1355.2万 USD | −558.7万 USD |
| 净利润 | −1112.5万 USD | −1021万 USD | −1010.7万 USD | −1234万 USD | −404.1万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
